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Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for
neuroendocrine carcinoma
Aim: Primary cutaneous neuroendocrine carcinoma,
or Merkel cell carcinoma (MCC), cannot be distin-
guished morphologically from small-cell neuroen-
docrine carcinomas (SmCC) from other sites.
Immunohistochemistry is required to confirm cuta-
neous origin, and is also used for detection of sentinel
lymph node (SLN) metastases of MCC. Cytokeratin 20
(CK20) expression is commonly used for these pur-
poses, but is negative in some MCC cases, and has
unclear specificity. We evaluated immunohistochem-
istry for neurofilament and CK20 in MCC compared
with SmCC from other sites.
Methods and results: We evaluated neurofilament
expression in 55 MCC specimens from 39 unique
patients, including nine CK20-negative MCC tumours.
Neurofilament expression was observed in 42 of 55
(76.4%) MCC cases, including seven of nine (77.8%)
CK20-negative MCC cases. Neurofilament was
expressed in nine of 12 (75%) Merkel cell poly-
omavirus-positive tumours and five of 10 (50%)
virus-negative tumours. Compared to a standard
immunohistochemical panel (cytokeratin cocktail and
CK20), neurofilament was 87.5% sensitive for detect-
ing SLN metastases. Neurofilament and CK20 expres-
sion was also assessed in 61 extracutaneous SmCC
from 60 unique patients, with primary sites including
lung (27), bladder (18), cervix (3), gastrointestinal
tract (3), sinonasal tract (2) and other sites (7). The
specificity of neurofilament and CK20 for MCC versus
non-cutaneous SmCC was 96.7% and 59.0%, respec-
tively.
Conclusions: Neurofilament has superior specificity to
CK20 in distinguishing MCC from non-cutaneous
SmCC. Neurofilament is frequently expressed in
CK20- and virus-negative MCC tumours. Limitations
of neurofilament immunohistochemistry include
lower sensitivity than CK20 and subtle staining in
some tumours. However, our findings indicate that
neurofilament is useful for excluding non-cutaneous
SmCC.
Keywords: cytokeratin 20, Merkel cell carcinoma, Merkel cell polyomavirus, neuroendocrine carcinoma,
neurofilament, sentinel lymph node, small-cell carcinoma
Introduction
Merkel cell carcinoma (MCC) is a rare but aggressive
cutaneous malignancy that arises primarily on sun-
damaged skin of elderly patients.1 Metastatic disease
to locoregional skin, regional lymph nodes and
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distant sites is a frequent occurrence. Estimated dis-
ease-specific mortality is 33–46%. Current evidence
supports the existence of two subtypes of MCC:
virus-positive MCC (VP-MCC), associated with the
oncogenic Merkel cell polyomavirus (MCPyV); and
virus-negative MCC (VN-MCC), with a high burden of
ultraviolet (UV)-associated mutations.2–5 Standard
management for MCC includes surgery, radiotherapy
and sentinel lymph node mapping.6 As a small blue
cell tumour with close morphological resemblance to
certain other tumour types, immunohistochemistry
has a critical role in diagnosis and accurate staging
of MCC.
Considering the aggressive potential of MCC, accu-
rate diagnosis is essential to timely management.
MCC may be mistaken for other cutaneous tumours,
and can be morphologically identical to metastasis
from extracutaneous small-cell neuroendocrine carci-
noma (SmCC), such as small-cell lung carcinoma
(SCLC). In addition, MCC may present as a metastasis
of unknown primary in lymph nodes or other extra-
cutaneous sites, raising the differential diagnosis of
SmCC from a range of sites. Standard diagnostic
immunohistochemistry for MCC includes cytokeratin
20 (CK20), neuroendocrine markers and often thy-
roid transcription factor 1 (TTF-1). Neuroendocrine
markers (including chromogranin A, synaptophysin
and/or CD56) are expressed in MCC, but may also be
expressed in other cutaneous carcinomas such as
basal cell carcinoma,1,7,8 and do not exclude extracu-
taneous SmCC or other poorly differentiated metas-
tases. TTF-1 expression is relatively specific for SCLC
in comparison to MCC, but is not expressed in
approximately 15% of SCLC, and may be expressed in
unusual cases of MCC.9–13 MCPyV has been shown
to be relatively specific for MCC compared to other
cutaneous carcinomas and SCLC, but is less sensitive
than other markers such as CK20,1,14–17 and is often
negative in CK20-negative MCC.18
Due to the high rates of lymph node metastasis for
even small MCC tumours, sentinel lymph node biopsy
is recommended by the National Comprehensive Can-
cer Network for all cases.6 As any size of metastatic
deposit is considered positive for staging purposes,
immunohistochemistry (especially for CK20 and
cytokeratin cocktail) is routinely used to assist in
detection of small metastases, including isolated
tumour cells.1,19 Cytokeratin cocktail is sensitive,
although staining of background lymph node fibrob-
lastic reticular cells may present a challenge to evalu-
ation for small metastases.20,21 CK20 staining in
lymph nodes is relatively specific for MCC; however,
sensitivity may be limited due to low or absent
expression in some tumours.1 No single neuroen-
docrine marker is consistently expressed in MCC, lim-
iting routine use of any given neuroendocrine marker
in SLN evaluation.1
Given the limitations of other markers, CK20 is
considered a key marker for MCC, with roles in
diagnosis and sentinel lymph node evaluation. In
MCC, CK20 is classically expressed in a paranu-
clear dot-like pattern, with or without cytoplas-
mic staining. Although CK20 is expressed in most
MCC,9–11,13,19,22–30 staining may be focal in some
tumours, requiring careful interpretation. Approxi-
mately 5–10% of MCC cases completely lack expression
of CK20, requiring more extensive immunophenotyp-
ing and clinical correlation for diagnostic confirmation.
CK20 is considered to be specific for MCC relative to
other cutaneous carcinomas.1 Although CK20 expres-
sion has been reported to favour MCC over most extra-
cutaneous SmCCs, a minority of SCLC may express
CK20,9,10,27,30 and CK20 is frequently expressed in
parotid and cervical SmCC.13,30,31
Neurofilament is an intermediate filament expressed
in the majority of MCC, classically in a paranuclear
dot-like pattern similar to cytokeratins.9,23,29,32,33
Limited reports suggest that neurofilament expression
is specific to MCC relative to SCLC.23,32 However,
neurofilament expression has not been characterised
in a spectrum of extracutaneous SmCCs. Although
one study of sentinel lymph node biopsies for MCC
that included five lymph node metastases found neu-
rofilament to be less sensitive than CK20,19 this find-
ing has not been replicated in a larger cohort. In
addition, studies have been limited regarding the rela-
tionship of neurofilament expression to CK20 expres-
sion and MCPyV status.34
To define the diagnostic utility of neurofilament for
the diagnosis and staging of MCC more clearly, we
examined neurofilament and CK20 immunohisto-
chemical expression in a cohort of 116 neuroen-
docrine tumours, including MCC and SmCC from
diverse anatomical sites.
Materials and methods
C A S E C O H O R T
The study was conducted following a protocol
approved by the Institutional Review Board at the
University of Michigan (HUM00045834, approval
date 8/11/2016). Cases of MCC and SmCC were iden-
tified using a retrospective search of the pathology
database and previously assembled study sets at the
University of Michigan. Cases were selected on the
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 504–513.
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basis of tumour adequacy for staining. Cases for the
CK20-negative MCC cohort were required to have
complete absence of CK20 expression (confirmed by
repeat CK20 immunohistochemistry as described
below). Haematoxylin and eosin (H&E)-stained sec-
tions were reviewed by P.W.H. to confirm the diagno-
sis. The MCC cohort consisted of 55 specimens from
39 unique patients, including nine previously charac-
terised CK20-negative MCC tumours,18,35 and a set of
16 matched primary tumour-sentinel lymph node
metastasis CK20-positive MCC pairs. All metastases
were at least 1 mm in maximal dimension. For 22
MCC cases from 14 unique patients, the results of
MCPyV immunohistochemistry previously performed
for other studies were available.2,35,36 The SmCC
cohort consisted of 61 tumours from 60 unique
patients, with primary sites including lung (27), blad-
der (18), cervix (3), gastrointestinal tract (3), sinona-
sal tract (2), ovary (3), breast (1), prostate (1),
thymus (1) and larynx (1). Five negative lymph
nodes from non-MCC cases served as negative
controls.
I M M U N O H I S T O C H E M I S T R Y
Neurofilament (Cell Marque, Rocklin, CA, USA;
mouse monoclonal clone 2F11, prediluted) and CK20
(Cell Marque; ConfirmTMrabbit monoclonal antibody,
1:200 dilution) immunohistochemistry was per-
formed using the Ventana automated immunostainer
(Ventana, Tucson, AZ, USA).5–7 Neurofilament stain-
ing was performed on all tumours. CK20 staining
was performed on all extracutaneous SmCC, all
CK20-negative MCC and a subset of CK20-positive
MCC. All parameters were scored independently by
two dermatopathologists (P.W.H. and D.R.F.) in a
blinded manner, with any major discordance resolved
by a third independent scorer (M.P.C.). CK20 and
neurofilament immunohistochemistry was scored as
either negative or positive, with expression in a mini-
mum of five tumour cells necessary to consider a
tumour positive. CK20 and neurofilament staining
pattern was assessed as paranuclear dot-like and/or
cytoplasmic/membranous. Intensity of staining was
scored (0–3). Final intensity values were averaged
from individual scores and placed into the following
categories: negative (0), weak (1–1.4), moderate
(1.5–2.4) and strong (2.5 and above). Extent of stain-
ing (focal <10%, intermediate = 10–75%, diffuse
>75%) was determined by consensus amongst inde-
pendent scorers. Upon initial case review, there was a
substantial rate of interobserver variability in distinc-
tion of intermediate from diffuse extent, and of
moderate from strong intensity; therefore, these cate-
gories were grouped as intermediate/diffuse and mod-
erate/strong for purposes of statistical analysis.
Specific scores for each case are shown in Table S1.
S T A T I S T I C A L A N A L Y S I S
To determine significant difference between variables,
Fisher’s exact test or analysis of variance was used
for categorical variables, and the Mann–Whitney U-
test or Student’s t-test was used for continuous vari-
ables. Statistical significance was defined as a P-value
less than 0.05. Analyses were performed using
Graphpad Prism version 7 software (Graphpad Soft-
ware Inc., La Jolla, CA, USA).
Results
N E U R O F I L A M E N T E X P R E S S I O N I N M C C
To evaluate the sensitivity of neurofilament expression
for the diagnosis and staging of MCC, we assembled a
cohort of 55 MCC tumours, including primary-metas-
tasis pairs and previously characterised CK20-negative
MCC tumours (Table 1, Table S1).18 Neurofilament
expression was observed in 42 of 55 (76.4%) MCC
cases, including seven of nine (77.8%) CK20-negative
MCC cases (Figure 1A,B). Most cases displayed diffuse
or intermediate extent of expression across the
tumour, with 7.3% of cases staining focally (Fig-
ure 1C). Intensity of neurofilament staining was weak
(34.5%) or moderate (41.8%). Staining pattern was
consistently paranuclear dot-like when present. The
extent and intensity of neurofilament staining in
CK20-negative cases was similar to other MCC
(Table 1, Figures 2 and 3). In all three tumours (from
two patients) in our cohort that displayed a compo-
nent of squamous differentiation (Table S1, cases 17A,
17B and 32), neurofilament was weakly expressed at
an intermediate percentage in the neuroendocrine
component and absent in the squamous component.
Among cases previously characterised for the presence
of MCPyV, neurofilament was expressed in nine of 12
(75%) VP-MCC tumours and five of 10 (50%) VN-MCC
tumours (Table 1, Table S1). The intensity of neurofil-
ament expression was weak in most cases of VN-MCC
that displayed expression (Table 1).
N E U R O F I L A M E N T E X P R E S S I O N I N L Y M P H N O D E
M E T A S T A S E S
Compared to the gold standard (cytokeratin cocktail
and CK20), neurofilament displayed a sensitivity of
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 504–513.
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87.5% and specificity of 100% for detecting lymph
node metastases (Table S1). The presence or absence
of neurofilament expression was consistent between
the primary tumours and matched metastases in 10
of 16 pairs. Of the remaining pairs, five were negative
for neurofilament expression in the primary tumour
and positive in the matched metastasis (with interme-
diate to diffuse expression in the metastasis), whereas
one pair was weakly positive for neurofilament in the
primary tumour and negative in the matched metas-
tasis (Table S1).
With the exception of neural structures, no back-
ground staining of lymph node elements by neurofila-
ment was observed. Although neurofilament
expression has been reported in cutaneous melanocy-
tic nevi,37 nodal nevi lacked neurofilament expression
in all cases examined (none of five). Therefore, neuro-
filament expression was highly specific for MCC
metastases.
N E U R O F I L A M E N T A N D C K 2 0 S T A I N I N G I N
D I S T I N G U I S H I N G M C C F R O M N O N - C U T A N E O U S
S M C C
CK20 and neurofilament expression was evaluated in
non-cutaneous SmCC to determine which immuno-
histochemical marker is best able to distinguish MCC
from non-cutaneous neuroendocrine carcinomas.
CK20 expression was observed in 25 of 61 (41.0%)
non-cutaneous SmCC cases, resulting in a specificity
of 59% for distinction from MCC (Table 2, Fig-
ures 1D, 2 and 3). CK20 staining was examined in
one matched pair of SCLC tumours in which the pri-
mary tumour was negative for CK20, and a liver
metastasis displayed focal CK20 expression.
Our criteria for considering tumours CK20 positive
were relatively permissive (expression in at least five
cells, with at least weak intensity staining), therefore
we considered whether performance might be
MCC MCC SmCCMCC
(CK20-negative)
A B C D
Figure 1. Representative cases of neurofilament expression in neuroendocrine carcinomas. A, Diffuse dot-like neurofilament expression in a
CK20-positive Merkel cell carcinoma (MCC). B, Intermediate dot-like neurofilament expression in a CK20-negative MCC. C, Focal neurofila-
ment expression in MCC. D, Absence of neurofilament expression in extracutaneous small-cell neuroendocrine carcinomas (SmCC).
MCC SmCC #1 SmCC #2MCC
(CK20-negative)
A B C D
Figure 2. Representative cases of CK20 expression in neuroendocrine carcinomas. A, Diffuse strong CK20 expression in Merkel cell carci-
noma (MCC). B, Absence of CK20 expression in CK20-negative MCC. C, Representative example of focal CK20 expression in an extracuta-
neous small-cell neuroendocrine carcinoma (SmCC). D, Representative example of diffuse CK20 expression in an SmCC.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 504–513.
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improved by more stringent scoring criteria. Specificity
for MCC was improved by requiring moderate/strong
intensity of staining (specificity 71.8%) or expression
in >10% of tumour cells (specificity 85.2%); however,
these more stringent criteria also excluded 28.2% of
MCC cases previously scored as positive by the original
criteria. Requiring tumours to display a component of
paranuclear dot-like CK20 staining improved speci-
ficity slightly (to 65.5%) and excluded relatively few
MCC previously scored as positive (5.1%). Considering
only tumours with positive CK20 staining, expression
in >10% of tumour cells was significantly associated
with MCC relative to SmCC (P < 0.01), whereas stain-
ing intensity and the presence of paranuclear dots
were not significantly associated with cutaneous origin
(P = 0.56 and 0.21, respectively).
Neurofilament was expressed much more fre-
quently in MCC compared to non-cutaneous SmCC
(P < 0.0001), and was 96.7% specific for this distinc-
tion (Table 1, Figures 1A–D and 3). Two non-cuta-
neous SmCC cases were positive for neurofilament: a
CK20-negative sinonasal SmCC with focal weak
expression and a SCLC with focal expression of both
neurofilament and CK20 (Table S1). Both MCC and
non-cutaneous SmCC displayed paranuclear dot-like
staining for neurofilament when positive.
Discussion
Merkel cell carcinoma is an aggressive cutaneous car-
cinoma with high frequency of recurrence and
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Figure 3. Extent, intensity, and pattern of immunohistochemical expression of neurofilament and CK20 in Merkel cell carcinoma (MCC) and
non-cutaneous small-cell carcinoma (SmCC) tumours. Figures include cases for which the given parameter could be scored. [Colour figure
can be viewed at wileyonlinelibrary.com]
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metastasis. Immunohistochemistry is critical to con-
firm the diagnosis of MCC and assist in excluding the
possibility of extracutaneous SmCC. Metastatic MCC of
unknown primary presenting in a lymph node or other
extracutaneous site may be especially challenging to
distinguish from non-cutaneous SmCC. Several diag-
nostic markers have been investigated for distinction of
MCC from extracutaneous SmCC, including stains pro-
posed to be expressed with relative specificity in MCC
(CK20, neurofilament, TdT, MCPyV large T antigen) or
SCLC (TTF1, MASH1 ASCL1).1,9,11–13,16,17,23,25–
27,32,33,38,39 With few exceptions, studies have not
evaluated expression patterns in SmCC from anatomi-
cal sites other than lung. In addition, although sub-
stantial gene expression differences exist between VP-
MCC and VN-MCC,40 few studies have accounted for
MCC viral status when comparing staining patterns
with extracutaneous SmCC. As CK20-negative MCC
are often also negative for MCPyV,18 studies that
address useful diagnostic markers in this subset of
MCC are particularly necessary.
CK20 is a major diagnostic marker for MCC. CK20
expression has been proposed to be specific for MCC
relative to extracutaneous SmCC. However, multiple
reports have described CK20 expression in a minority
of SCLC9,10,27 and a significant percentage of parotid
and cervical SmCC.13,30,31 Our findings confirm and
expand upon this observation, demonstrating that
CK20 expression can occur in a minority of SmCC
from multiple anatomical sites. CK20 was frequently
expressed in cervical SmCC, bladder SmCC and a
minority of SCLC. The specificity of CK20 staining for
MCC was only slightly improved by requiring
tumours to display a component of paranuclear dot-
like staining. More stringent requirements for the
extent and intensity of CK20 staining improved speci-
ficity, but also resulted in exclusion of a significant
fraction of MCC cases. A limitation of our study is
that CK20 expression was a controlled variable in
our MCC cohort, precluding determination of certain
statistical associations for CK20 including sensitivity.
In agreement with previous reports,9,23,29,32,33 we
find that neurofilament is a sensitive and specific
marker for MCC. Neurofilament was expressed in a
substantial fraction of cases regardless of MCPyV
and CK20 status. Although we observed relatively
lower sensitivity for neurofilament in VN-MCC, our
sample size was too small for robust statistical com-
parison. Neurofilament expression was highly specific
for MCC, with no expression detected in the vast
majority of extracutaneous SmCC. Of 61 SmCC
tumours evaluated, only two displayed focal neurofil-
ament staining (one case of SCLC and one sinonasal
SmCC). Unlike a previous study,31 we did not
observe neurofilament expression in cervical SmCC.
A limitation of our study is that primary parotid
SmCC cases were not available for study. An addi-
tional limitation is that our study cohort included
few MCC tumours with squamous differentiation, in
which context neurofilament has been reported to
be less sensitive.34
Given the challenge of identifying small metastatic
deposits of MCC in lymph nodes, immunohistochem-
istry of sentinel lymph node biopsies plays a critical
role in accurate MCC staging. A previous report
examining a small number of positive sentinel lymph
nodes (n = 5) found that neurofilament had low sen-
sitivity (20%) for detection of sentinel lymph node
metastases.19 In a larger cohort of lymph node
metastases (n = 16), we find that neurofilament is
useful for detection of metastatic MCC. Neurofilament
is less sensitive than CK20, displays less intense stain-
ing than CK20 in most cases and may be sparsely or
focally expressed, therefore our findings do not sup-
port the use of neurofilament in place of CK20 in sen-
tinel lymph node evaluation for most cases of MCC.
However, for cases with focal or absent CK20 expres-
sion in the primary tumour, neurofilament represents
a highly specific and reasonably sensitive stain along-
side cytokeratin cocktail for the evaluation of sentinel
lymph node biopsies. Of note, in some cases neurofila-
ment was effective in identifying lymph node metas-
tases despite the apparent lack of expression in the
primary tumour. A limitation of our study is that sin-
gle-cell metastases were not examined, therefore we
cannot comment on the sensitivity of neurofilament
in this specific context.
In summary, given its superior specificity to CK20,
neurofilament should be considered for suspected
MCC cases in which additional confirmation of cuta-
neous origin is necessary. Neurofilament may be
especially useful in cases of SmCC of unknown pri-
mary. However, rare cases of extracutaneous SmCC
may display neurofilament expression. Neurofilament
is frequently expressed in CK20-negative MCC, and is
sensitive regardless of MCPyV status. Finally, neurofil-
ament may also be useful in detection of sentinel
lymph node deposits in cases of MCC with focal or
absent CK20 expression.
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